Lilly's new tau protein blood testing study, JAMA AD, is expected to achieve high-precision diagnosis.

On July 28, a major international study of Eli Lilly and Company's new blood test P-tau217 to diagnose Alzheimer's disease (AD) was published in the Journal of the American Medical Association (JAMA)The results showed that P-tau217 (the tau protein no217 sucone phosphate) was significantly better than other blood-based biomarkers or magnetic resonance imaging (MRI) in distinguishing AD from other neurodegenerative diseasesP-tau217 shows prospects for application in the diagnosis of AD, as well as in people known to be at genetic risk, and for people with susceptible genetic mutations, a faster-than-expected date of onset, such as 20 years before the onset of early cognitive impairmentFor years, the diagnosis of Alzheimer's disease has been based on the characteristics of amyloid plaques and tau protein entanglements in the brain, and are usually discovered after the patient's deathOver the past two years, great progress has been made in the development of blood tests for amyloid proteinsAccording to the new study, measuring P-tau217, a tau protein found in tangles, can provide a relatively sensitive and accurate detection indicator of plaque and tangles that could be used to diagnose Alzheimer's disease in lifeThe cross-sectional study had three queues, including patients from the Arizona Neuropathology Queue, the Swedish BioFINDER-2 queue, and the Colombia Autosochy Dominant AD Relative QueueThe results showed that p-tau217 was able to accurately identify AD from other neurodegenerative diseases in the Arizona-based neuropathology team and the Swedish BioFINDER-2 studyIn the third Colombian queue, the blood of the mutant carrier, P-tau217, increased 20 years before the expected symptoms appeared and was associated with memoryThe researchers evaluated the new P-tau217 blood test among 1,402 participants in well-known studies from Arizona, Sweden and Colombia for cognitive impairment and non-impairmentThe study, coordinated by Lund University in Sweden, included 81 Arizona participants from the Banner Sun Health Research Brain Donation Project who participated in clinical evaluations and provided blood samples in the final years of life, followed by neuropathological assessments after their deaths699 participants from the BioFINDER study in Sweden were evaluated for clinical, brain imaging, cerebrospinal fluid (CSF) and blood-based biomarkers; 522 carriers of Pathogensie Autosomal Dominant Alzheimer's disease (ADAD) disease-causing mutations and non-carriers from the world's largest ADAD queueIn the brain donation queue at the Banner Sun Institute of Health in Arizona, plasma P-tau217 was accurate in identifying brain donors and subsequent neuropathological diagnoses of "intermediate or highly likely Alzheimer's disease" (i.e., characterized by plaques, and entanglements that have spread to at least the temporal lobe memory area or beyond) with an accuracy rate of 98% for distinguishing between those with and without a "highly likely possibility of Alzheimer's disease" diagnosis;The higher P-tau217 measurements were associated with higher brain tangles counts only in those who also had amyloid plaquesIn the BioFINDER study in Sweden, the test ingested patients clinically diagnosed with Alzheimer's disease and other neurodegenerative diseases with 96% accuracy, similar to tau protein PET scans and CSF biomarkers, better than several other blood tests and MRI measurements, and 93% accuracy in patients with and without tau protein PET scan abnormalitiesIn the Colombian queue, the test was able to distinguish between mutant carriers and non-carriers, 20 years earlier than their estimated age of mild cognitive impairment In each analysis, P-tau217 performed better than other research blood tests of P-tau181 (another group of tau tangles, another blood test to diagnose ad potential molecules) Dr Oskar Hansson, professor of clinical memory studies at Lund University in Sweden and leading the Swedish BioFINDER study, said: "P-tau217 blood testing has great potential for diagnosis, early detection and research of Alzheimer's disease While more needs to be done to optimize testing and more extensive testing prior to clinical application, blood testing may become particularly useful to improve identification, diagnosis and care in primary care facilities Dr Jeffrey Dage, senior research consultant at Lilly, said: "Distinguishing AD pathology from other types of cognitive impairment is an important step in our understanding of how AD affects patients As the study progresses, we will be able to identify AD earlier, and we hope to conduct further research on the right population in the future From diagnostic tools to treatment opportunities, Lilly and Avid remain committed to strong research in AD Lilly and avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly and its wholly-owned subsidiary dedicated to the discovery and development of radiological drugs and imaging methods, are conducting research on P-tau217 as a Biomarker for AD Pathology Lilly will continue to optimize the testing and determine its potential role in the clinic Additional research data on P-tau217 will be presented at upcoming scientific meetings, including the Alzheimer's Association International Conference (AAIC) (July 27-31) and the Alzheimer's Clinical TrialS Conference (CATD) (November 4-7) Source: s1 New blood test show great promise in the diagnosis of The Sied Retrived 2020-7-28 from sP-tau217 Blood Test Show High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA Retrived 2020-7-28 from